WHAT IS CLAIMED IS:

1. The combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0.

2. The combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine according to claim 1 wherein the method of treating results in promoting healing of the diabetic ulcer.

3. The combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine according to claim 1 or claim 2 wherein the method of treating comprises oral administration of a nutritional composition comprising the beta-hydroxy-beta-methylbutryate, arginine, and glutamine.

4. The combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine according to any one of claims 1-3 wherein the diabetic ulcer is a diabetic foot ulcer.

5. The combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine according to any one of claims 1-4, wherein the individual is provided with from about 5.0 to about 20 grams per day of arginine, from about 5.0 to about 20 grams per day of glutamine, and from about 1.0 to about 10 grams per day of beta-hydroxy-beta-methylbutyrate.

6. The combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine according to any one of claims 1-5, wherein the combination comprises from about 10% to about 40% by weight arginine, from about 10% to about 40% by weight glutamine, and from about 1.0% to about 10% by weight calcium beta-hydroxy-beta-methylbutyrate.

7. The combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine according to any one of claims 1-6, wherein the combination further comprises at least one sweetener.

~~8. The combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine according to any one of claims 1-7, wherein the combination is administered to the individual for a period of at least 6 weeks.~~

~~9~~1. Use of the combination of beta-hydroxy-beta-methylbutyrate~~methylbutryate~~, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0.

~~10~~2. Use according to claim ~~9~~1, wherein the medicament is a nutritional composition suitable for oral administration to the diabetic individual.

~~11~~3. Use according to claim ~~9~~1 or ~~10~~2 wherein the diabetic ulcer is a diabetic foot ulcer.

~~12~~4. Use according to any one of claims ~~9~~1-~~11~~3, wherein the medicament provides the individual with from about 5.0 to about 20 grams per day of arginine, from about 5.0 to about 20 grams per day of glutamine, and from about 1.0 to about 10 grams per day of beta-hydroxy-beta-methylbutyrate.

~~13~~5. Use according to any one of claims ~~9~~1-~~12~~4, wherein the medicament comprises from about 10% to about 40% by weight arginine, from about 10% to about 40% by weight glutamine, and from about 1.0% to about 10% by weight calcium beta-hydroxy-beta-methylbutyrate.

~~14~~6. Use according to any one of claims ~~9~~1-~~13~~5, wherein the medicament further comprises at least one sweetener.

~~15~~7. Use according to any one of claims ~~9~~1-~~14~~6, wherein the medicament is administered to the individual for a period of at least 6 weeks.